Abstract
Abstract
Background
There is a high probability of gastroesophageal reflux after laparoscopic proximal gastrectomy for adenocarcinoma of the oesophagogastric junction (AEG). Various anti-reflux anastomotic methods are emerging in clinical practice; however, none of them have been widely accepted. We have innovated a new type of anti-reflux anastomotic method, named semi-embedded valve anastomosis. The aim of this study was to explore the feasibility and anti-reflux effect of the new anastomotic method.
Methods
The clinical data of 28 patients with Siewert II AEG who were treated by semi-embedded valve anastomosis were collected. The key point of the operation is to reconstruct a simulated valve and form an anti-reflux barrier similar to the physiological mechanism. The gastroesophageal reflux disease questionnaire (GerdQ) and classification of gastroesophageal reflux under electron microscopy were used to evaluate gastroesophageal reflux after the operation.
Results
The mean operative duration was 164.3 ± 19.0 min, the median intraoperative haemorrhage volume was 65 ml, the average number of lymph nodes dissected was 23 ± 2.6, the time for valve construction was 15.8 ± 3.2 min, the time for anastomotic reconstruction was 35.4 ± 4.8 min, the median time to first flatus was 3 d, and the median hospitalization duration was 12 d. There was one case of postoperative anastomotic stenosis. The GerdQ score [median (range)] was as follows: 2 (0–6), preoperation; 0 (0–8), 1 month postoperation; 2 (0–12), 3 months postoperation; and 3 (0–12), 6 months postoperation. The Wilcoxon signed-rank sum test was carried out at different times after the operation and the day before the operation, and the differences were not significant. There was one case of grade B gastroesophageal reflux according to the Los Angeles classification system among the gastrofibroscopic re-examination reports of 28 cases.
Conclusion
Semi-embedded valve anastomosis is safe and feasible after proximal gastrectomy for Siewert II AEG and has good anti-reflux effects.
Funder
Department of Health of Hebei Province
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Dubecz A, Solymosi N, Stadlhuber R, Schweigert M, Stein H, Peters J. Does the incidence of adenocarcinoma of the esophagus and gastric cardia continue to rise in the twenty-first century?—a SEER database analysis. J Gastrointest Surg. 2014;18(1):124–9.
2. Deans C, Yeo MS, Soe MY, Shabbir A, Ti T, So JB. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J Surg. 2011;35(3):617–24.
3. Siewert J, Stein H. Carcinoma of the gastroesophageal junction-classification, pathology and extent of resection. Dis Esophagus. 1996;9(3):173–82.
4. Blank S, Schmidt T, Heger P, Strowitzki MJ, Sisic L, Heger U, et al. Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach? Gastric Cancer. 2018;21(2):303–14. https://doi.org/10.1007/s10120-017-0746-1.
5. Li S-C, Zang L. Siewert type II adenocarcinoma of esophagogastric junction: treatment status. Mini-invasive Surg. 2019;3:15.